EIS Equity Investment Opportunity with 10.3x Returns
Please enter your details to request more information
Invest in the Future of Global Healthcare.
Minimum entry £10,000
Here at Frontier Diagnostics, we are transforming cancer diagnostics and treatment plans. Our rapid expansion plans include state-of-the-art laboratories and an online platform that will enable patients to directly access our services.
To fund our expansion, we are offering discounted shares to eligible investors on a limited basis.
Our early cancer detection and ongoing monitoring will revolutionise the future of Global Healthcare.
Our model is built around providing a specialised range of tests to healthcare professionals and patients, each designed to support personalised treatment plans covering:
EIS Benefits for Investors
Frontier Diagnostics Management Team
Biochemist and former Head of Asia Pacific for Thermo Fisher, and the Founder of DMB Diagnostics GmbH
Snr. Pharma with experience in Global Clinical Development and Medical Affairs. leading global teams in Phase II/III clinical trials
Chief Medical Officer at Teva Pharmaceuticals and as Vice President at Parexel Int
Distinguished general surgeon in Hepato- Pancreatic-Biliary (HPB) diseases, awarded a prestigious research fellowship from Royal College of Surgeons of England
To be able to deal with your enquiry effectively we will need to contact you via telephone and/or email. By enquiring you consent to being contacted and you consent to your data being stored in accordance with European GDPR regulations. Privacy Policy
Disclaimer: Any person accessing this website or page and considering potential investment opportunities featured here, should make their own commercial assessment of an investment opportunity after seeking the advice of an appropriately authorised or regulated financial advisor. This website or page should not be construed as advice or a personal recommendation to any prospective investor. Investments of this nature carry risks to your capital and can go up or down. Past performance is not indicative of future results. Suitable appropriately qualified investors, sophisticated and high net worth investors only.